GM_profile

Geoffrey Masuyer, PhD

Co-Founder, CEO


A structural biologist, Geoffrey has worked on the development of toxin-based therapeutics for more than 15 years, including academic collaborations with Ipsen BioInnovation (UK), and Applied Molecular Transport Inc. (USA) at the University of Bath (UK) and Stockholm University (Sweden).



PS_profile

Pål Stenmark, PhD

Co-Founder, Vice-CEO


A structural biologist, Pål has more than 20 years experience in academia working on structure-based drug design and research on the botulinum neurotoxins.


Pål is Professor of Neurochemistry at Stockholm University (Sweden).